

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

Phospho-Zap-70 (Tyr493) Antibody

RRID:AB_2217457

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2704, RRID:AB_2217457

Antibody Information

URL: http://antibodyregistry.org/AB_2217457

Proper Citation: Cell Signaling Technology Cat# 2704, RRID:AB_2217457

Target Antigen: Phospho-Zap-70 (Tyr493)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP

Antibody Name: Phospho-Zap-70 (Tyr493) Antibody

Description: This polyclonal targets Phospho-Zap-70 (Tyr493)

Target Organism: rat, h, m, mouse, r, human

Antibody ID: AB_2217457

Vendor: Cell Signaling Technology

Catalog Number: 2704

Record Creation Time: 20250820T030509+0000

Record Last Update: 20250820T151828+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Zap-70 (Tyr493) Antibody.

No alerts have been found for Phospho-Zap-70 (Tyr493) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Otsuka S, et al. (2024) Calcineurin is an adaptor required for assembly of the TCR signaling complex. *Cell reports*, 43(8), 114568.

Xu X, et al. (2024) Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity. *Immunity*, 57(12), 2755.

Cheng J, et al. (2023) Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment. *Cell metabolism*, 35(6), 961.

Jenkins BJ, et al. (2023) Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. *Cell metabolism*, 35(7), 1132.

Wiede F, et al. (2022) PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. *Cancer discovery*, 12(3), 752.

Palmer DC, et al. (2022) Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. *Med (New York, N.Y.)*, 3(10), 682.

Wang Y, et al. (2021) NAD⁺ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. *Cell reports*, 36(6), 109516.

Guha J, et al. (2021) Disc Large Homolog 1 Is Critical for Early T Cell Receptor Micro Cluster Formation and Activation in Human T Cells. *Vaccines*, 9(12).

Mintz MA, et al. (2019) The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis. *Immunity*, 51(2), 310.

Celis-Gutierrez J, et al. (2019) Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. *Cell reports*, 27(11), 3315.

Waight JD, et al. (2018) Selective Fc γ R Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. *Cancer cell*, 33(6), 1033.

Zhao Y, et al. (2018) Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. *Cell reports*, 24(2), 379.